<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">toxreview</journal-id><journal-title-group><journal-title xml:lang="ru">Токсикологический вестник</journal-title><trans-title-group xml:lang="en"><trans-title>Toxicological Review</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0869-7922</issn><issn pub-type="epub">3034-4611</issn><publisher><publisher-name>Federal Scientific Center of Hygiene named after F.F. Erisman</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36946/0869-7922-2020-3-26-32</article-id><article-id custom-type="elpub" pub-id-type="custom">toxreview-306</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КОНКУРС НАУЧНЫХ РАБОТ МОЛОДЫХ УЧЕНЫХ И СПЕЦИАЛИСТОВ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>COMPETITION OF SCIENTIFIC WORKS OF YOUNG SCIENTISTS AND SPECIALISTS</subject></subj-group></article-categories><title-group><article-title>ИЗУЧЕНИЕ МЕХАНИЗМА ПУЛЬМОНОТОКСИЧЕСКОГО ДЕЙСТВИЯ ДИХЛОРАНГИДРИДА УГОЛЬНОЙ КИСЛОТЫ</article-title><trans-title-group xml:lang="en"><trans-title>STUDY OF THE MECHANISM OF PULMONOTOXICOLOGICAL ACTION OF CARBONYL DICHLORIDE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Толкач</surname><given-names>П. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Tolkach</surname><given-names>P. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Толкач Павел Геннадьевич </p><p>кандидат медицинских наук, преподаватель кафедры военной токсикологии и медицинской защиты </p><p>191044, г. Санкт-Петербург</p></bio><bio xml:lang="en"><p>Tolkach Pavel Gennad`evich </p><p>194044, Saint Petersburg </p></bio><email xlink:type="simple">pgtolkach@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Военно-медицинская академия им. С.М. Кирова МО РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>S.M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>24</day><month>06</month><year>2020</year></pub-date><volume>0</volume><issue>3</issue><fpage>26</fpage><lpage>32</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Толкач П.Г., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Толкач П.Г.</copyright-holder><copyright-holder xml:lang="en">Tolkach P.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.toxreview.ru/jour/article/view/306">https://www.toxreview.ru/jour/article/view/306</self-uri><abstract><p>Аварийные ситуации на промышленных объектах, которые используют фосген в качестве исходного сырья для синтеза химических соединений, могут стать источником формирования стойкого очага химического заражения. Фосген оказывает ацилирующее действие на макромолекулы компонентов аэрогематического барьера, что приводит к развитию токсического отёка лёгких. На сегодняшний день не известно, какой компонент аэрогематического барьера (слой сурфактанта, альвеолоциты или эндотелиоциты) служит первичной мишенью для этого токсиканта. В проведённом экспериментальном исследовании (in vitro) было выявлено, что воздействие фосгена на сурфактант (ООО Биосурф, Россия) не приводило к снижению основных фосфолипидов (дипальмитоилфосфатидилхолин), однако способствовало увеличению содержания соединений из группы лизофосфатидилэтаноламинов (провоспалительные агенты). В исследовании (in vivo) при внутрибрюшинном введении фосгена лабораторных животным (крысам) признаков воспалительной реакции со стороны компонентов брыжейки тонкой кишки не обнаружено. Патологических изменений в лёгких и печени животных, получавших фосген внутрибрюшинно, также не выявлено. Результаты проведённого исследования свидетельствуют о том, что эндотелиоциты, расположенные в аэрогематическом барьере не играют ведущей роли в инициации провоспалительного каскада в тканях лёгких после ингаляционного воздействия фосгена. Первичным источником провоспалительных медиаторов, приводящих к развитию токсического отёка лёгких, могут быть альвеолоциты и/или компоненты сурфактанта.</p></abstract><trans-abstract xml:lang="en"><p>Accidents at industrial facilities that use phosgene as a feedstock for the synthesis of chemical compounds can become a source of formation of a persistent focus of chemical contamination. Phosgene has an acylating effect on the macromolecules of the components of the aerogematic barrier, which leads to the development of toxic pulmonary edema. To date, it is not known which component of the aerogematic barrier (surfactant layer, alveolocytes or endotheliocytes) serves as the primary target for this toxicant. It has been found in vitro that the action of phosgene on the surfactant (Biosurf Ltd., Russian Federation) did not lead to a decrease in the content of main phospholipids (dipalmitoylphosphatidylcholine), but contributed to an increase in the content of compounds from the group of lysophosphatidylethanolamines (proinflammatory agents). In in vivo study with intraperitoneal administration of phosgene to laboratory animals (rats), there were no signs of an inflammatory reaction of the components of the mesentery of the small intestine. Pathological changes in the lungs and liver of animals that received phosgene intraperitoneal were also not detected. The results of the study indicate that endotheliocytes located in the aerogematic barrier do not play a leading role in the initiation of a proinflammatory cascade in lung tissues after inhaled exposure to phosgene. The primary sources of proinflammatory mediators that lead to the development of toxic pulmonary edema may be alveolocytes and/or surfactant components.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>фосген</kwd><kwd>токсический отёк лёгких</kwd><kwd>воспалительные процесс</kwd><kwd>аэрогематический барьер</kwd><kwd>серозно-гематический барьер</kwd></kwd-group><kwd-group xml:lang="en"><kwd>phosgene</kwd><kwd>toxic pulmonary edema</kwd><kwd>inflammatory process</kwd><kwd>aerogematic barrier</kwd><kwd>serous-hematic barrier</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Global Phosgene Market 2017. Digital Journal. 2017. Available at: http://www.digitaljournal.com/pr/3387723. Дата обращения 03.03.2019 года.</mixed-citation><mixed-citation xml:lang="en">Global Phosgene Market 2017. Digital Journal. 2017. Available at: http://www.digitaljournal.com/pr/3387723 (accessed 3 March 2019).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sciuto A.M., Hurt H.H. Therapeutic treatments of phosgene-induced lung injury. Inhal. Toxicol. 2004; 16: 565-80.</mixed-citation><mixed-citation xml:lang="en">Sciuto A.M., Hurt H.H. Therapeutic treatments of phosgene-induced lung injury. Inhal. Toxicol. 2004; 16: 565-80.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lange D.W., Meulenbelt J. Do corticosteroids have a role in preventing or reducing acute toxic lung injury caused by inhalation of chemical agents? Clin. Toxicol. 2011; 49: 61-71.</mixed-citation><mixed-citation xml:lang="en">Lange D.W., Meulenbelt J. Do corticosteroids have a role in preventing or reducing acute toxic lung injury caused by inhalation of chemical agents? Clin. Toxicol. 2011; 49: 61-71.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Holmes W.W., Keyser B.M., Paradiso D.C., Ray R. Andres D.K., Benton B.J. [et al.] Conceptual approaches for treatment of phosgene inhalation-induced lung injury. Toxicol. Lett. 2016; 244: 8-20.</mixed-citation><mixed-citation xml:lang="en">Holmes W.W., Keyser B.M., Paradiso D.C., Ray R. Andres D.K., Benton B.J. [et al.] Conceptual approaches for treatment of phosgene inhalation-induced lung injury. Toxicol. Lett. 2016; 244: 8-20.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Розенберг О.А. Препараты легочного сурфактанта при острых и хронических заболеваниях легких (Часть I). Общая реаниматология. 2014; 10(3): 51-73.</mixed-citation><mixed-citation xml:lang="en">Rozenberg O.A. Pulmonary surfactants for acute and chronic lung diseases (Part I). General Reanimatology. 2014; 10(3): 51-73 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Schmidt R., Meier U, Yabut-Perez M., Walmrath D. Grimminger F, Seeger W. [et al.] Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia / Am J Respir Crit Care Med. 2001; 163: 95-100.</mixed-citation><mixed-citation xml:lang="en">Schmidt R., Meier U, Yabut-Perez M., Walmrath D. Grimminger F, Seeger W. [et al.] Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia / Am J Respir Crit Care Med. 2001; 163: 95-100.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Хурцилава О.Г. ред. Оксидативный стресс и воспаление: патогенетическое партнерство: Монография. СПб. Изд-во СЗГМУ им. И.И.Мечникова; 2012.</mixed-citation><mixed-citation xml:lang="en">Khurtsilava O.G. ed. Oxidative stress and inflammation: pathogenic partnership. SPb, NWSMU named after I.I. Mechnikov; 2012 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ерохин В.В., Лепеха Л.Н., Ерохина М.В., Ловачева О.В. Сурфактантная система при туберкулезе легких. М.: ФГБУ «ЦНИИТ» РАМН; 2013.</mixed-citation><mixed-citation xml:lang="en">Erohin V.V., Lepeha L.N., Erohina M.V., Lovacheva O.V. Surfactant system for pulmonary tuberculosis. M .: FSBI «TsNIIT» RAMS; 2013 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Mills S.E. ed. Histology for pathologists, 3rd ed. Lippincott Willis &amp; Wilkins, 2007: 547-562.</mixed-citation><mixed-citation xml:lang="en">Mills S.E. ed. Histology for pathologists, 3rd ed. Lippincott Willis &amp; Wilkins, 2007: 547-562.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Nagel W., Kuschinsky W. Study of the permeability of the isolated dog mesentery. Europ. J. Clin. Invest. 1970; 1: 149-54.</mixed-citation><mixed-citation xml:lang="en">Nagel W., Kuschinsky W. Study of the permeability of the isolated dog mesentery. Europ. J. Clin. Invest. 1970; 1: 149-54.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Suárez-García S., Arola L., PascualSerrano A., Arola-Arnal A., Aragonès G., Bladé C. [et al.] Development and validation of a UHPLC-ESI-MS/MS method for the simultaneous quantification of mammal lysophosphatidylcholines and lysophosphatidylethanolamines in serum. Journal of Chromatography. 2017; 1055-1056: 86–97.</mixed-citation><mixed-citation xml:lang="en">Suárez-García S., Arola L., PascualSerrano A., Arola-Arnal A., Aragonès G., Bladé C. [et al.] Development and validation of a UHPLC-ESI-MS/MS method for the simultaneous quantification of mammal lysophosphatidylcholines and lysophosphatidylethanolamines in serum. Journal of Chromatography. 2017; 1055- 1056: 86–97.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Filipczak P.T., Senft A.P., Seagrave J.C., Weber W., Kuehl P.J., Fredenburgh L.E. [et al]. NOS-2 inhibition in phosgene-induced acute lung injury. Toxicol. Scien. 2015; 146(1): 89-100.</mixed-citation><mixed-citation xml:lang="en">Filipczak P.T., Senft A.P., Seagrave J.C., Weber W., Kuehl P.J., Fredenburgh L.E. [et al]. NOS-2 inhibition in phosgene-induced acute lung injury. Toxicol. Scien. 2015; 146(1): 89-100.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
